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Summary
The disease course of COVID-19 varies from asymptomatic infection to critical con-
dition leading to mortality. Identification of prognostic factors is important for pre-
vention and early treatment. We aimed to examine whether obesity is a risk factor
for the critical condition in COVID-19 patients by performing a meta-analysis. The
review protocol was registered onto PROSPERO (CRD42020185980). A systematic
search was performed in five scientific databases between 1 January and 11 May
2020. After selection, 24 retrospective cohort studies were included in the qualita-
tive and quantitative analyses. We calculated pooled odds ratios (OR) with 95% con-
fidence intervals (CIs) in meta-analysis. Obesity was a significant risk factor for
intensive care unit (ICU) admission in a homogenous dataset (OR = 1.21, CI:
1.002-1.46; I2 = 0.0%) as well as for invasive mechanical ventilation (IMV)
(OR = 2.05, CI: 1.16-3.64; I2 = 34.86%) in COVID-19. Comparing body mass index
(BMI) classes with each other, we found that a higher BMI always carries a higher
risk. Obesity may serve as a clinical predictor for adverse outcomes; therefore, the
inclusion of BMI in prognostic scores and improvement of guidelines for the intensive
care of patients with elevated BMI are highly recommended.
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1 | INTRODUCTION
In December 2019, a series of pneumonia cases of unknown origin
emerged in Wuhan, China. On 7 January 2020, a novel coronavirus,
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was
identified as the source of infection.1 As of 14 June 2020, Coronavi-
rus Disease-19 (COVID-19) infection has been reported in more than
seven million cases.2
The disease course of COVID-19 varies in a broad spectrum,
from asymptomatic infection to influenza-like symptoms as well as
to severe pneumonia leading to acute respiratory distress syndrome
(ARDS).2 Recognition of prognostic factors associated with adverse
clinical outcomes is essential for prevention and early treatment.
Certain diseases, including diabetes mellitus, hypertension, cardio-
vascular diseases or different types of cancer, have been already
identified as predisposing factors to adverse outcomes in COVID-
19.3 As these diseases are frequently associated with excessive
body fat mass resulting in various hormonal, metabolic and inflam-
matory changes, adipose tissue may play an important role in the
mechanism of the progression of COVID-19 and obesity might be
an important risk factor as well.4–7 Patients with obesity constantly
have higher leptin and lower adiponectin levels, as well as they have
higher concentrations of pro-inflammatory cytokines such as tumour
necrosis factor (TNF)-alpha, monocyte chemoattractant protein
(MCP)-1 and interleukin (IL)-6 produced mainly by adipose tissue,
which may contribute to the impaired immune response.8,9 These
conditions may influence inflammatory and immune responses.
Another contributor could be the sedentary lifestyle alone or
together with insulin resistance that influences the immune
response to microbial agents by impaired macrophage differentiation
and modulation of proinflammatory cytokine levels giving way to
the invasion of infectious pathogens.10,11
Interestingly, the obesity survival paradox has been described
in certain diseases such as community-acquired pneumonia,
where despite the increased risk of developing pneumonia, an
inverse association could be observed between obesity and
mortality.6 To the contrary, in the 2009 H1N1 pandemic, obesity
was identified as an independent risk factor of severe disease,
hospitalization and death.5,12,13 Recent data have suggested that
obesity, as seen in H1N1, can also be a disadvantageous factor to
COVID-19.14,15
Although several articles discussing the impact of the body mass
index (BMI) on the need for intensive care unit (ICU) admission or
invasive mechanical ventilation (IMV) in COVID-19 are available, a
definite conclusion has not been drawn yet. Therefore, we aimed to
clarify the association between the patients' BMI and ICU admission
and IMV requirement.
2 | METHODS
We report our systematic review and meta-analysis in accordance
with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) Statement (Table S1).16 The review protocol was
registered on the PROSPERO International Prospective Register of
Systematic Reviews (CRD42020185980). We did not deviate from
the protocol except for expanding the exclusion criteria. We decided
to perform additional meta-regressions to assess the correlation
between BMI values and rate of ICU admission/IMV. These analyses
had their own additional eligibility criteria (detailed in Section 2.2.).
2.1 | Search strategy
A systematic search was performed in five scientific databases—
Medline (via PubMed), Embase, Cochrane Central Register of Con-
trolled Trials (CENTRAL), Scopus and Web of Science—for studies
published between 1 January 2020 and 11 May 2020. The following
search key was used in all databases without any other filters or
restrictions: (‘covid 19’) OR (‘Wuhan virus’) OR (‘coronavirus’) OR
(‘2019 nCoV’) OR (‘SARS-cov-2’). Reference lists of the eligible articles
and the citing articles (via Google Scholar search engine) were also
screened to capture all relevant studies.
2.2 | Selection and eligibility criteria
After the removal of duplicates using a reference management
software (EndNote X9, Clarivate Analytics), three pairs of review
authors independently screened titles, abstracts and then full-texts
against predefined eligibility criteria (each pair screened one-third of
the pool of records) to accelerate the selection process. A third review
author resolved the conflicts.
There were no restrictions on the study designs eligible for
inclusion. The inclusion criteria specified any peer-reviewed studies
that reported on BMI classes of patients with confirmed SARS-CoV-2
infection comparing the proportion of ICU admission or IMV
requirement between each group. We excluded studies with fewer
than 10 patients.
Regarding meta-regression, those studies were eligible that
contained information on mean/median BMI and event rate of IMV
and ICU in the study population.
From both meta-analyses and meta-regression, we excluded
studies with preselected population, specifically SARS-CoV-2-infected
patients with certain coexisting diseases or conditions that potentially
cause malnutrition (e.g., cystic fibrosis) or significantly influence body
weight (pregnancy, paediatric population).
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2.3 | Data extraction
Two independent review authors extracted data from the eligible
studies into a standardized data collection form. All disagreements
were resolved by an independent third author. The following data
were extracted from each included study: authors, publication year,
digital object identifier, study site, study design, protocol number, age,
gender distribution, number of patients in each reported BMI range,
number of patients with IMV in each reported BMI range, number of
patients with ICU admission in each reported BMI range, odds ratios
for IMV and ICU admission regarding BMI groups.
2.4 | BMI categories
We defined BMI classes based on the World Health Organization
(WHO) guidelines.17 We included Asian and Caucasian populations in
the same analysis—with their corresponding BMI cut off—only in
meta-analyses comparing patients with obesity and patients without
obesity. We applied different cut-off values for obesity in Asian-
Pacific (obesity >25 kg/m2) and Caucasian (obesity >30 kg/m2)
population.17
2.5 | Risk of bias assessment
Based on the recommendations of Cochrane Prognosis Methods
Group (PMG), a modified version of the Quality in Prognostic Studies
(QUIPS) tool was used by the two independent review authors to
assess the quality of the studies included.18 Any disagreement was
resolved by a third party.
2.6 | Statistical analysis
We performed all meta-analytic calculations with Comprehensive
Meta-Analysis (Version 3) statistical software (Biostat, Inc.,
Engelwood, MJ, USA). For data synthesis, we used the methods
recommended by the working group of the Cochrane Collaboration.
Pooled odds ratios (ORs) with their 95% confidence intervals (CIs)
were calculated from raw data of the articles except for one
article,19 where the given OR and the CI were used. The random
effect model with the estimation of DerSimonian and Laird was
used in all cases.20 Heterogeneity was tested using Cochrane's
Q and the I2 statistics. I2 statistic represents the percentage of the
total variability across studies: 30% to 60%, 50% to 90% and 75%
to 100% corresponded to moderate, substantial and considerable
degrees of heterogeneity, based on the Cochrane's handbook for
Systematic Reviews of Interventions.21 We considered the Q test
significant if P < 0.1. Publication bias was examined by visual
inspection of funnel plots.
To examine the effect of BMI on the event rate of IMV, meta-
regression was applied. We examined if the regression coefficient is
equal to zero. We assessed R2 analogue, which is the explained
variances of the models. We calculated corresponding P values and I2-
test values.
3 | RESULTS
3.1 | Results of search and selection
We described the selection process in detail in the PRISMA flow chart
(Figure 1). We identified a total of 33,987 records, 24 of which were
included in the qualitative and quantitative syntheses. Nine studies
were included in the meta-analyses, and 20 articles in the meta-
regression. Five studies contained data for both the meta-analysis and
the meta-regression.
3.2 | Characteristics of studies included
3.2.1 | Meta-analysis
The characteristics of the studies included in the meta-analyses are
presented in Table 1 and Table S2. Six studies with 2,770 patients
reported on ICU admission, the proportion of which ranged from 9%
to 43%. Five studies with 509 patients reported on IMV requirement,
the proportion of which ranged from 58% to 78%.
3.2.2 | Meta-regression
The characteristics of the studies included in the meta-regression
analysis are presented inTable S3.
3.3 | Association between BMI and ICU admission
3.3.1 | Qualitative and quantitative synthesis
comparing BMI classes
Lodigiani et al reported 15.4% versus 15.9% ICU admission ratio
among patients with BMI less than 25 and with BMI greater than or
equal to 25, respectively.22 In another study, a higher ICU admission
ratio was observed among patients with BMI values greater than or
equal to 25 compared with patients with a BMI of 25 or lower (46.4%
vs. 26.3%, respectively).19
Our pooled analysis of six studies showed that COVID-19
patients with obesity have a significantly higher risk for ICU admission
(OR = 1.21, CI: 1.002-1.46; I2 = 0.0%).19,22–26 This result is depicted in
Figure 2.
There were not enough studies to compare ICU admission ratios
between different BMI ranges.
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TABLE 1 Characteristics of the included studies
Study (country) Cohort type
N0 of patients
(female %) Ageb
BMI categories (N0)
Event
Event N0
(%)
Normal
(<25)
Overweight
(25-30)
Obese
(>30)
Nonobese vs. obesea
Hu L et al (China) Retrospective 294 (49%) 61 229 65 ICU admission 25 (9%)
Itelman E et al
(Israel)
Retrospective 162 (35%) 52 131 31 ICU admission 26 (16%)
Kalligeros M et al
(USA)
Retrospective 103 (38%) 60 44 59 ICU admission 44 (43%)
Lighter J et al
(USA)
Retrospective 1759 (NR) NR 1,010 749 ICU admission 431 (25%)
Lodigiani C et al
(Italy)
Retrospective 361 (32%) 66 274 87 ICU admission 57 (16%)
Ong S et al
(Singapore)
Retrospective 91 (NR)
27 (NR)
55 51
12
40
15
ICU admission
IMV need
27 (30%)
16 (59%)
Normal weight vs. overweight or obese
Bhatraju PK et al
(USA)
Retrospective 23 (38%) 64 3 7 13 IMV need 18 (78%)
Caussy C et al
(France)
Retrospective 291 (NR) NR 74 121 96 IMV need 170 (58%)
Kalligeros M et al
(USA)
Retrospective 44 (34%) 60 5 14 25 IMV need 29 (66%)
Simonnet A et al
(France)
Retrospective 124 (27%) 60 17 48 59 IMV need 89 (72%)
Note. All studies were conducted in 2020.
Abbreviations: ICU, intensive care unit; IMV, invasive mechanical ventilation; NR = not reported.
aDifferent cut-off values were used to define obesity in Asian and Caucasian population.
bMean or median.
F IGURE 1 Preferred Reporting in
Systematic Reviews and Meta-analyses
(PRISMA) flowchart showing the
selection process
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3.3.2 | Multivariate analyses
Kalligeros et al evaluated the association between different BMI
ranges and ICU admission with multivariate logistic regression analy-
sis. They found that BMI greater than or equal to 35 carries a six times
higher risk for ICU admission compared with BMI lower than
25 (OR = 6.16, CI: 1.42-26.66).19 Their results are summarized in
Table S4.
3.3.3 | Meta-regression
Because of insufficient data, we could not perform meta-regression to
assess the correlation between BMI and ICU admission. The BMI
values of the eligible studies and the corresponding ICU admission
ratios are presented inTable S2.
3.4 | Association between BMI and IMV
requirement
3.4.1 | Qualitative and quantitative synthesis
comparing BMI classes
We found that IMV is significantly more likely to occur in patients
with BMI greater than or equal to 25 compared with those with BMI
lower than 25 (OR = 2.63, CI: 1.64-4.22; I2 = 0.0%).15,27,28 The result
of this analysis is shown in Figure S1.
The comparison of patients with obesity and without obesity rev-
ealed an increased risk for IMV among patients with obesity
(OR = 2.05, CI: 1.16-3.64; I2 = 34.86%).15,19,25,27,28 The forest plot dis-
playing this result is found in Figure 3.
There were enough studies to statistically compare the reported
BMI ranges (<25, 25-30, 30-35 and ≥35) with each other. We found
that the higher BMI ranges always carry a significantly higher risk for
IMV compared with the categories with a lower range. The BMI sub-
group analyses are shown in Figure 4.
3.4.2 | Multivariate analyses
Kalligeros et al assessed the association between different BMI ranges
and IMV with multivariate logistic regression analysis. They found that
BMI greater than or equal to 35 carries a six times higher risk for IMV
compared with BMI lower than 25.19 Simonnet et al reported an
increased risk for IMV among patients with higher BMI using multivar-
iate logistic regression analysis.15 They found that BMI ranges of
25 to 30, 30 to 35 and BMI greater than or equal to 35 carry a signifi-
cantly higher risk for IMV compared to patients with BMI lower than
25. The results of these studies are summarized inTable S4.
3.4.3 | Meta-regression
Meta-regression scatter plot representing the correlation between
BMI and IMV is shown in Figure S2.15,28–34 No correlation was found
F IGURE 2 Odds ratios for intensive care unit
admission in patients with obesity versus patients
without obesity. BMI, body mass index; CI,
confidence interval; ICU, intensive care unit
F IGURE 3 Odds ratios for invasive
mechanical ventilation (IMV) in patients with
obesity versus patients without obesity. CI,
confidence interval
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(P = 0.8890, Q = 0.02, I2 = 63.39%, pheterogeneity = 0.0078). However,
the analysis provides information only for a narrow BMI range.
3.5 | Risk of bias assessment and publication bias
Funnel plots indicating the possibility of publication bias are found in
Figures S3 and S4. Egger's tests could not be performed to detect
publication bias due to the number of included studies in each
hypothesis. Visual assessment of the funnel plots did not imply
asymmetry.
The results of the risk of bias assessment of individual studies are
shown inTable S5.
3.6 | Assessment of heterogeneity
There was no statistical heterogeneity in the meta-analyses except for
comparison of patients with obesity and without obesity regarding
IMV requirement (I2 = 34.86%, moderate level of statistical heteroge-
neity). The P values related to I2 were over 0.01.
4 | DISCUSSION
According to our meta-analysis and systematic review, patients with
higher BMI have a greater risk for ICU admission and especially for
IMV in all comparisons.
The knowledge about the role of obesity in the disease course of
respiratory tract infections is limited. Previous studies suggested that
obesity might be associated with poor prognosis in COVID-19.35–37
Subsequent data have called attention to the higher need for
intensive care and mechanical ventilation.15,19,28 However, there is no
previous meta-analysis in this topic, and the available studies cannot
lead to definitive conclusions because of the low sample sizes and
their retrospective nature. Nevertheless, gathering knowledge of the
clinical characteristics of these patients is of utmost importance as this
could facilitate adequate management and resource allocation.38
4.1 | Obesity and ICU admission
Due to scarce data, we could not perform a conclusive meta-
regression to assess the correlation between BMI and ICU admission,
although it is well known that obesity carries enhanced risk of chronic
diseases that could contribute to the increased need for ICU admis-
sion and unfavourable outcomes in COVID-19 patients. Unfortu-
nately, initial studies neglected the anthropometric data of patients.39
Nevertheless, we found in our pooled analysis that obesity is
associated with a higher risk for ICU admission in COVID-19 patients.
Since the lower endpoint of the CI in this analysis is close to the zero
effect, we feel that it needs confirmation by further studies. This
would be particularly important because limited ICU capacity has cau-
sed great concern worldwide. Indeed, leading officials of intensive
care societies worldwide have proposed to increase ICU capacity
because health care should provide intensive care to everyone who
needs it.40
The association between obesity and poor clinical outcomes is
certainly multifactorial since obesity itself is widely associated with
several prognostic factors.7 In COVID-19 patients, hypertension, dia-
betes and cardiovascular problems are the most common com-
orbidities19 that may share similar pathways with obesity related to
the renin-angiotensin system (RAS).41 Obesity modulates the RAS
activity,42 which can lead to pathological processes in COVID-19.43 In
F IGURE 4 Odds ratios for invasive
mechanical ventilation (IMV) between
patient groups with different BMI ranges
(<25, 25-30, 30-35 and ≥35). BMI = body
mass index, CI = confidence interval
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this connection, another interesting point was proposed by Lighter
et al, namely that a BMI of 35 and above is a risk factor for ICU
admission in patients aged less than 60 years, but not in the elderly.26
Ong et al presented similar findings on IMV requirement.25 According
to the previous studies, obesity seems to increase general mortality
risk at older ages, but to a lesser extent than at younger ages.44,45
4.2 | Obesity and the need for IMV
Among COVID-19 patients admitted to the ICU, 40% to 100% of
patients require IMV.33,46,47 Excessive body mass and obstructive
sleep apnea might complicate different forms of respiratory support
and endotracheal intubation.48,49 Prolonged endotracheal intubation
time, which is more frequently present in patients with obesity, also
increases the risk of infection of the medical staff.50 These are of
particular importance considering that we have shown a greater risk
for IMV in patients with higher BMI in all comparisons.
In general, several studies in ICU have shown that patients with
higher BMI require IMV more frequently and for a longer period.51,52
This could be partly explained by the reduced pulmonary reserves,
anatomical alterations of the chest wall; hence, it is not surprising that
these patients have a higher risk for progressing into ARDS.53,54
Moreover, obesity may also alter immune response. Protective
immune functions might be disabled; for instance, vaccination success
can be poor in the case of obesity.55 Both hyperinflammation and
enhanced coagulation have been reported as frequent finding in both
COVID-19 and obesity.56,57 These features and findings in COVID-19
patients may explain our results, but until specifically investigated, this
remains a hypothesis.
4.3 | Strengths
To our knowledge, this is the first meta-analysis about this topic
despite its importance. We followed a rigorous methodology, and
besides meta-analyses, we also performed meta-regression and the
assessment of publication bias. No considerable heterogeneity was
detected in any analyses. To assess the risk-increasing effect of
obesity as accurately as possible, we also conducted analyses that
compare BMI ranges with each other.
4.4 | Limitations
A crucial limitation is that our results are from a sparse number of
retrospective studies. In addition, our analysis can be limited by the
different strategies of different hospitals regarding ICU admission and
an indication of IMV, which has been scarcely defined across the
included studies. Besides, the BMI distribution can also be largely
different between Asian and Caucasian populations. We sought
to correct this in our analysis, but the limitation could not be
completely avoided.
4.5 | Implications for future practice
Based on our findings, it is highly recommended to measure anthropo-
metric parameters of patients and include BMI in the development of
a specific COVID-19 risk assessment score in the future. As patients
with higher BMI have a greater risk for ICU admission and IMV,
patients with obesity may need special monitoring and earlier escala-
tion of treatment. Therefore, it is important to amend guidelines for
COVID-19 risk stratification and treatment with special attention to
patients with obesity. Besides, prevention might also be important.
Returning waves of COVID-19 pandemic cannot be excluded; there-
fore, it remains important to support weight loss and regular physical
activity and also to elaborate vaccination programmes with special
regard to the higher risk groups including individuals with
elevated BMI.
4.6 | Implications for future research
Because of the limited information on this topic, it should be subject
to future studies. Multivariate analyses should be conducted to
examine whether obesity is an independent risk factor, as it has
been suggested in the case of H1N1 influenza.13 Anthropometric
parameters of patients with COVID-19 should be included in future
studies.
Conducting further basic research would be crucial for a better
understanding of the pathogenesis of COVID-19 in patients
with obesity. Literature suggests that adipose tissue may serve as
a reservoir for certain pathogens (e.g., Influenza A virus and
Mycobacterium tuberculosis).58 It would be worth examining this in
terms of COVID-19 as well.
5 | CONCLUSION
In summary, our meta-analysis and systematic review revealed that
obesity is a significant risk factor for ICU admission and particularly
for IMV requirement in COVID-19. It may serve as a clinical predictor
for risk stratification models; therefore, measurement of anthropo-
metric and metabolic parameters in COVID-19 would be crucial.
Patients with obesity should be closely monitored and might need
escalation of therapy earlier to avoid unfavourable clinical outcomes.
As returning waves of the pandemic are expected, improvement of
guidelines for patients with obesity is highly recommended.
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